Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Lee, Ann Sing
Zee, Benny C. Y.
Cheung, Foon Yiu
Kwong, Philip
Cheng, Ashley Chi Kin
Lai, Maria
Kwok, Chloe
Chong, Marc
Jolivet, Jacques
Chiang, C. L.
Leung, K. C.
Siu, Steven
Lee, Conrad
Tung, Stewart Yuk
机构：
[1] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[4] Queen Mary Hosp, North Point, Hong Kong, Peoples R China
[5] Princess Margaret Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Aegera Therapeut Pharmasci Inc, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Kowloon, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4105
引用
收藏
页数：1
相关论文
共 50 条
  • [21] XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML
    Bing Z. Carter
    Duncan H. Mak
    Stephen J. Morris
    Gautam Borthakur
    Elihu Estey
    Anna L. Byrd
    Marina Konopleva
    Hagop Kantarjian
    Michael Andreeff
    Apoptosis, 2011, 16 : 67 - 74
  • [22] XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML
    Carter, Bing Z.
    Mak, Duncan H.
    Morris, Stephen J.
    Borthakur, Gautam
    Estey, Elihu
    Byrd, Anna L.
    Konopleva, Marina
    Kantarjian, Hagop
    Andreeff, Michael
    APOPTOSIS, 2011, 16 (01) : 67 - 74
  • [23] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Schwartz, Lawrence
    Ricci, Sergio
    Amadori, Dino
    Santoro, Armando
    Figer, Arie
    De Greve, Jacques
    Douillard, Jean-Yves
    Lathia, Chetan
    Schwartz, Brian
    Taylor, Ian
    Moscovici, Marius
    Saltz, Leonard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) : 4293 - 4300
  • [24] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [25] Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Shao, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Ding, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Ghassan K. Abou-Alfa
    Chia-Jui Yen
    Chih-Hung Hsu
    Joseph O’Donoghue
    Volkan Beylergil
    Shutian Ruan
    Neeta Pandit-Taskar
    Bolorsukh Gansukh
    Serge K. Lyashchenko
    Jennifer Ma
    Peter Wan
    Yu-Yun Shao
    Zhong-Zhe Lin
    Catherine Frenette
    Bert O’Neil
    Lawrence Schwartz
    Peter M. Smith-Jones
    Toshihiko Ohtomo
    Takayoshi Tanaka
    Hideo Morikawa
    Yuko Maki
    Norihisa Ohishi
    Ya-Chi Chen
    Tamara Agajanov
    Frederic Boisserie
    Laura Di Laurenzio
    Ray Lee
    Steven M. Larson
    Ann-Lii Cheng
    Jorge A. Carrasquilo
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 421 - 429
  • [27] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Yen, Chia-Jui
    Hsu, Chih-Hung
    O'Donoghue, Joseph
    Beylergil, Volkan
    Ruan, Shutian
    Pandit-Taskar, Neeta
    Gansukh, Bolorsukh
    Lyashchenko, Serge K.
    Ma, Jennifer
    Wan, Peter
    Shao, Yu-Yun
    Lin, Zhong-Zhe
    Frenette, Catherine
    O'Neil, Bert
    Schwartz, Lawrence
    Smith-Jones, Peter M.
    Ohtomo, Toshihiko
    Tanaka, Takayoshi
    Morikawa, Hideo
    Maki, Yuko
    Ohishi, Norihisa
    Chen, Ya-Chi
    Agajanov, Tamara
    Boisserie, Frederic
    Di Laurenzio, Laura
    Lee, Ray
    Larson, Steven M.
    Cheng, Ann-Lii
    Carrasquilo, Jorge A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (02) : 421 - 429
  • [28] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Perspective Phase II Study of Combination Sorafenib Plus Mitomycin-C in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
    Dima, G.
    Lucia, M.
    La Gattuta, G.
    Toscano, R.
    Olivito, V.
    Talarico, R.
    Cervo, G. L.
    Filippelli, G.
    ONCOLOGY, 2009, 77 : 142 - 143
  • [30] PERSPECTIVE PHASE II STUDY OF COMBINATION SORAFENIB PLUS MITOMYCIN-C IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Gianluca, Dima
    Maria, Lucia
    Gaetana, La Gattuta
    Rosa, Toscano
    Virginia, Olivito
    Rosa, Talarico
    Luca, Cervo Gian
    Gianfranco, Filippelli
    ANNALS OF ONCOLOGY, 2009, 20
12345